look at the great data that Aradigm has exhibited in both CF and and Bronchiectasis. They could have gotten that entire platform for a lot less then they paid for this one.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.